Search results for "Targeted Therapy"

showing 10 items of 297 documents

Novel therapeutical approaches to managing atherosclerotic risk

2021

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to cardiometabolic risk factors, lipids alterations, hypolipidemic agents, nutraceuticals, hypoglycaemic drugs, atherosclerosis, endothelial dysfunction, and inflammation was performed. There are several therapeutic strategies including Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs), and nutraceuticals t…

QH301-705.5InflammationReview030204 cardiovascular system & hematologyPharmacologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineLipid oxidationmedicineAnimalsHumans030212 general & internal medicineMolecular Targeted TherapyPhysical and Theoretical ChemistryEndothelial dysfunctionBiology (General)Molecular BiologyQD1-999SpectroscopyInnovative therapiesMolecular signalingVascular diseasebusiness.industryPCSK9Organic ChemistryGeneral MedicineProprotein convertasemedicine.diseaseAtherosclerosisComputer Science ApplicationsManagementChemistryInflammationsAtheromaOxidative stressHypolipidemic Agentslipids (amino acids peptides and proteins)Nutraceuticalsmedicine.symptombusiness
researchProduct

Unmet needs and challenges in gastric cancer: The way forward

2014

AbstractAlthough the incidence of gastric cancer has fallen steadily in developed countries over the past 50years, outcomes in Western countries remain poor, primarily due to the advanced stage of the disease at presentation. While earlier diagnosis would help to improve outcomes for patients with gastric cancer, better understanding of the biology of the disease is also needed, along with advances in therapy. Indeed, progress in the treatment of gastric cancer has been limited, mainly because of its genetic complexity and heterogeneity. As a result, there is an urgent need to apply precision medicine to the management of the disease in order to ensure that individuals receive the most appr…

Quality Controlmedicine.medical_specialtyDrug developmentAuditDiseasePathogenesisMalignancyUnmet needsGastrectomyStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyRegistriesIntensive care medicineQuality of Health CareRandomized Controlled Trials as Topicbusiness.industryIncidence (epidemiology)CancerGenomicsGeneral Medicinemedicine.diseasePrecision medicineSurgeryEuropeTreatmentOncologyRadiology Nuclear Medicine and imagingDrug DesignQuality of LifeHeterogeneitybusinessGastric cancerDelivery of Health CareDeveloped countryAlgorithms
researchProduct

QSAR multi-target in drug discovery: a review.

2013

The main purpose of the present review is to summarize the most significant works up to date in the field of multi-target QSAR (mt-QSAR), in order to emphasize the importance that this technique has acquired over the last decade. Unlike traditional QSAR techniques, mt-QSAR permits to calculate the probability of activity of a given compound against different biological or pharmacological targets. In simple terms, a single equation for multiple outputs. To emphasize more the importance of the mt-QSAR in the field of drug discovery, we also present a novel mt-QSAR model, made on purpose by our research group, for the prediction of the susceptibility of Gram + and Gram - anaerobic bacteria.

Quantitative structure–activity relationshipDrug discoveryQuantitative Structure-Activity RelationshipGeneral MedicineComputational biologyBiologyBioinformaticsMulti targetDrug DiscoverySingle equationMolecular MedicineAnimalsHumansAnaerobic bacteriaMolecular Targeted TherapyAlgorithmsProbabilityCurrent computer-aided drug design
researchProduct

Caveolin-1, breast cancer and ionizing radiation

2015

Breast cancer (BC) recovery has increased in recent years thanks to efforts of Omics-based research in this field. However, despite the important results obtained, BC remains a complex multifactorial pathology that is difficult to treat appropriately. Caveolin-1 (CAV1), the basic constituent protein of specialized plasma membrane invaginations called caveolae, is emerging as a potential therapeutic biomarker in BC. This factor may modulate BC response to chemotherapy and radiation therapy. In addition, recent reports describe the key role of CAV1 during cell response to oxidative stress. The aim of the present review was to describe the biological roles of CAV1 in BC considering its contras…

RadiotherapyAnimalCAV1; biomarker; breast cancer; ionizing radiation; review; Animals; Biomarkers Tumor; Breast Neoplasms; Caveolin 1; Cell Transformation Neoplastic; Female; Gene Expression Regulation Neoplastic; Humans; Molecular Targeted Therapy; Radiotherapy; Receptor Epidermal Growth Factor; Radiation IonizingCaveolin 1reviewBreast NeoplasmsErbB ReceptorsGene Expression Regulation Neoplasticbreast cancerCell Transformation NeoplasticCAV1Radiation IonizingBiomarkers TumorAnimalsHumansbiomarkerFemaleMolecular Targeted TherapyReceptor Epidermal Growth Factorionizing radiationBreast NeoplasmHuman
researchProduct

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer

2021

The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. However, despite the therapeutic success of existing therapies targeting HER2, tumours invariably relapse. Therefore, there is an urgent need to improve our understanding of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. It is well known that the tumour microenvironment (TME) has a significant impact on cancer behaviour. Cancer-associated fibroblasts (CAFs) are essential components of the…

Receptor ErbB-2Cancer-associated fibroblastQH301-705.5breast cancer; HER2-positive; tumour microenvironment; targeted therapy; trastuzumab; resistance; cancer-associated fibroblast; label-free proteomics; miRNABreast NeoplasmsDocetaxelAntibodies Monoclonal HumanizedArticleCatalysisInorganic ChemistryresistanceDrug Delivery SystemsLabel-free proteomicsbreast cancerCancer-Associated FibroblastsCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsHumansPhysical and Theoretical ChemistryBiology (General)skin and connective tissue diseasesMolecular BiologyQD1-999SpectroscopymiRNAOrganic ChemistryGeneral Medicinetargeted therapyHER2-positiveComputer Science ApplicationstrastuzumabChemistryDrug Resistance NeoplasmFemaletumour microenvironmentInternational Journal of Molecular Sciences
researchProduct

miR-29s: A family of epi-miRNAs with therapeutic implications in hematologic malignancies

2015

A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced p…

ReviewTumor initiationhematologic malignancieEpigenesis GeneticmicroRNAmedicineAnimalsHumansMolecular Targeted TherapyEpigeneticsmiR-29cbiologymiR-29abusiness.industrymiR-29bCancerDNA Methylationhematologic malignanciesmedicine.diseasemultiple myelomaMicroRNAsHistoneOncologyHematologic NeoplasmsDNA methylationImmunologyCancer researchbiology.proteinHistone deacetylaseSignal transductionbusiness
researchProduct

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

2015

Abstract: The diagnosis and treatment of hepatocellular carcinoma (HCC) underwent a huge advancement in the last years. Recently, microRNAs (miRNAs) have been also studied to provide a new tool for early diagnosis of high risk patients, for prognostic classification to identify those patients who benefit cancer treatment and for predictive definition to select the right targeted drug. In this review we revised all the available data obtained to explore the role of miRNAs in HCC. This analysis led to identification of miRNAs which could gain a diagnostic, prognostic or predictive role. The results of studies on miRNAs involved in HCC are initial and far from providing scientific evidences to…

Serum0301 basic medicineCarcinoma HepatocellularHepatocellular carcinomaPrognosimedicine.medical_treatmentBioinformaticsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinePrognostic classificationBiomarkers TumormedicineHumansProspective cohort studyHigh risk patientsbusiness.industryLiver NeoplasmsMicroRNAHematologyPrognosismedicine.diseaseCancer treatmentClinical PracticeMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaHuman medicineDiagnosis; Hepatocellular carcinoma; MicroRNA; Prognosis; Serum; Targeted therapy; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessDiagnosiCritical Reviews in Oncology/Hematology
researchProduct

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

2015

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second-line treatments are a significant unmet medical need, and several biologic agents have been tested in recent years, with poor results. Therefore, angiogenic pathways and the cytokine cascade remain possible targets in HCC. Recent studies suggest a role of epigenetic processes, associated with the initiation and development of HCC. In this field, DNA methylation, micro-RNAs (miRNAs) and tumor microenvironment cells became a possible new target for HCC treatment. Areas covered: This review explains the possible role of DNA methylation and histone deacetylase inhibito…

Settore MED/06 - Oncologia MedicaClinical BiochemistrytivantinibEpigenesis GeneticAntineoplastic Agentchemistry.chemical_compoundHistone Deacetylase InhibitorDrug DiscoveryTumor MicroenvironmentMolecular Targeted TherapyplateletmicroRNALiver Neoplasmshepatocellular carcinomaSorafenibVEGFLiver NeoplasmHepatocellular carcinomaDNA methylationMolecular MedicineepigeneticHumanmedicine.drugPhenylurea CompoundSorafenibNiacinamideCarcinoma HepatocellularAntineoplastic AgentsBiologymicroRNAmedicineAnimalsHumansEpigeneticsTivantinibPharmacologyTumor microenvironmentAnimalDrug Discovery3003 Pharmaceutical SciencePhenylurea CompoundsDNA Methylationmedicine.diseasedigestive system diseasesHistone Deacetylase InhibitorsMicroRNAschemistryDrug DesignImmunologyCancer researchHistone deacetylaseExpert opinion on therapeutic targets
researchProduct

THE FINGERPRINT OF THE HUMAN GASTROINTESTINAL TRACT MICROBIOTA: A HYPOTHESIS OF MOLECULAR MAPPING

2017

The precise etiology of Inflammatory Bowel Disease (IDB) remains unclear and several factors are believed to play a role in its development and progression, including the composition of microbial communities resident in the gastrointestinal tract. Human intestinal microbiota are extensive with at least 15,000-36,000 bacterial species. However, thanks to the new development in sequencing and molecular taxonomic methodologies, our understanding of the microbiota population composition, dynamics, and ecology has greatly increased. Intestinal microbiota play a critical role in the maintenance of the host intestinal barrier homeostasis, while dysbiosis, which involves reduction in the microbiome…

Settore MED/12 - Gastroenterologiagastrointestinal tract microbiota dysbiosis Inflammatory Bowel Diseases molecular mapping fingerprintInflammatory Bowel DiseasesDNA FingerprintingAnti-Bacterial AgentsBacterial Typing TechniquesGastrointestinal MicrobiomeGastrointestinal TractSettore MED/18 - Chirurgia GeneraleRNA Ribosomal 16SDNA Barcoding TaxonomicDysbiosisHomeostasisHumansMolecular Targeted TherapyPrecision MedicineOligonucleotide Array Sequence Analysis
researchProduct

HSP-MOLECULAR CHAPERONES IN CANCER BIOGENESIS AND TUMOR THERAPY: AN OVERVIEW

2012

Molecular chaperones, many of which are heat-shock proteins (HSPs), are an important class of molecules with various functions. Pathological conditions in which chaperones become etiological and/or pathogenic factors are called chaperonopathies, and are classified into by defect, by excess, and by "mistake". In the latter case, the chaperone is structurally and functionally normal but paqrtecipates in pathwais that favor diseases, aòlthough in some cases the chaperone may have post-translational modifications that may lead it to change its location and function and, thus, to become pathogenic. For example, HSP-chaperones are involved in acrcinogenesis in various ways, so that some forms of …

Settore MED/18 - Chirurgia GeneraleCell Transformation NeoplasticSettore MED/09 - Medicina InternaSettore BIO/16 - Anatomia UmanaNeoplasmsmolecular chaperones chapoeronig system chaperonology chaperonopathy by mistake cancer HSP60 chaperonin chaperonopathy.AnimalsHumansMolecular Targeted TherapyCancer VaccinesHeat-Shock Proteins
researchProduct